Shattuck Labs, Inc. Payments to Acquire Debt Securities, Available-for-sale
Shattuck Labs, Inc. (STTK) reported Payments to Acquire Debt Securities, Available-for-sale of $144.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $144.80M.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $67.00K.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $43.42M, a 45.31% increase year-over-year.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $43.42M, a 53.59% decline from fiscal 2024.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $93.55M, a 17.33% increase from fiscal 2023.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $79.73M, a 39.77% decline from fiscal 2022.
- Shattuck Labs, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $132.38M, a 35.14% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $144.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $144.87M 10-Q · filed 2026-08-11 | $144.87M derived: sum of 3 quarters · filed 2026-08-11 | $188.29M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $67.00K 10-Q · filed 2026-05-07 | $67.00K derived: sum of 2 quarters · filed 2026-05-07 | $43.48M derived: sum of 3 quarters · filed 2026-05-07 | $43.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $43.42M derived: sum of 2 quarters · filed 2026-03-05 | $43.42M derived: sum of 3 quarters · filed 2026-08-11 | $43.42M 10-K · filed 2026-03-05 |
| 2025-09-30 | $43.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $43.42M derived: sum of 2 quarters · filed 2026-08-11 | $43.42M 10-Q · filed 2025-11-06 | $43.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $29.88M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $29.88M derived: sum of 3 quarters · filed 2026-05-07 | $55.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $29.88M derived: sum of 2 quarters · filed 2026-03-05 | $55.28M derived: sum of 3 quarters · filed 2026-03-05 | $93.55M 10-K · filed 2026-03-05 |
| 2024-09-30 | $29.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $55.28M derived: sum of 2 quarters · filed 2025-11-06 | $93.55M 10-Q · filed 2025-11-06 | $98.48M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $25.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $63.67M 10-Q · filed 2025-08-14 | $68.61M derived: sum of 3 quarters · filed 2025-08-14 | $128.59M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $38.28M 10-Q · filed 2025-05-01 | $43.21M derived: sum of 2 quarters · filed 2025-05-01 | $103.19M derived: sum of 3 quarters · filed 2025-05-01 | $118.01M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $4.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $64.92M derived: sum of 2 quarters · filed 2025-03-27 | $79.73M derived: sum of 3 quarters · filed 2025-03-27 | $79.73M 10-K · filed 2025-03-27 |
| 2023-09-30 | $59.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $74.80M derived: sum of 2 quarters · filed 2024-11-14 | $74.80M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $14.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $14.81M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $132.38M 10-K · filed 2024-02-29 | |||
| 2021-12-31 | $39.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $86.81M derived: sum of 2 quarters · filed 2023-02-23 | $129.61M derived: sum of 3 quarters · filed 2023-02-23 | $204.09M 10-K · filed 2023-02-23 |
| 2021-09-30 | $47.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $90.60M derived: sum of 2 quarters · filed 2021-11-09 | $165.08M 10-Q · filed 2021-11-09 | $342.69M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $42.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $117.29M 10-Q · filed 2021-08-12 | $294.90M derived: sum of 3 quarters · filed 2022-03-15 | $297.74M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-03-31 | $74.48M 10-Q · filed 2021-05-10 | $252.10M derived: sum of 2 quarters · filed 2022-03-15 | $254.94M derived: sum of 3 quarters · filed 2022-03-15 | $254.94M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-12-31 | $177.61M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $180.45M derived: sum of 2 quarters · filed 2022-03-15 | $180.45M derived: sum of 3 quarters · filed 2022-03-15 | $183.19M 10-K · filed 2022-03-15 |
| 2020-09-30 | $2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $2.84M derived: sum of 2 quarters · filed 2021-11-09 | $5.58M 10-Q · filed 2021-11-09 | $14.59M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.74M 10-Q · filed 2021-08-12 | $11.75M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $2.74M 10-Q · filed 2021-05-10 | $11.75M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $9.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $44.27M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $35.26M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |